Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy

Journal of Pharmacology and Experimental Therapeutics

Volumn 340, Issue 1, 2012, Pages 64-72

  Bianchi, Roberto ^a,e   Cervellini, I ^b,e   Porretta Serapiglia, C ^a,e   Oggioni, N ^c   Burkey, B ^d   Ghezzi, P ^b,e   Cavaletti, G ^c   Lauria, G ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(2 ADAMANTYL)AMINO]ACETYL 2 CYANOPYRROLIDINE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; LONG ACTING DRUG; PKF 275 055; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; BODY WEIGHT; CONTROLLED STUDY; CORE TEMPERATURE; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG SELECTIVITY; ENZYME ACTIVITY; FLUID INTAKE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HORMONE BLOOD LEVEL; HYPERALGESIA; MALE; MECHANICAL HYPERALGESIA; MUSCLE MASS; NERVE CONDUCTION; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PAIN THRESHOLD; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; TEMPERATURE SENSITIVITY; THERMAL SENSITIVITY;

ADAMANTANE; ANIMALS; BEHAVIOR, ANIMAL; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING; EATING; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; MALE; NEURAL CONDUCTION; NITRILES; PAIN THRESHOLD; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 83955163338     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.181529     Document Type: Article

References (41)

1. Ahren B and Foley JE (2008) The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. Int J Clin Pract Suppl 8-14. (Pubitemid 351229609)
2. Asakawa T, Moritoh Y, Kataoka O, Suzuki N, Takeuchi K, and Odaka H (2009) A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. Life Sci 85:122-126.
3. Aytac U and Dang NH (2004) CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy. Curr Drug Targets Immune Endocr Metabol Disord 4:11-18. (Pubitemid 38854877)
4. Baggio LL and Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-2157. (Pubitemid 46711096)
5. Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, et al. (2007) The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 92:1249-1255. (Pubitemid 46556394)
6. Barnett A (2006) DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 60:1454-1470.
7. Berti-Mattera LN, Kern TS, Siegel RE, Nemet I, and Mitchell R (2008) Sulfasalazine blocks the development of tactile allodynia in diabetic rats. Diabetes 57:2801-2808.
8. Bianchi R, Buyukakilli B, Brines M, Savino C, Cavaletti G, Oggioni N, Lauria G, Borgna M, Lombardi R, Cimen B, et al. (2004) E\rythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A 101: 823-828. (Pubitemid 38121042)
9. Blandino-Rosano M, Perez-Arana G, Mellado-Gil JM, Segundo C, and Aguilar- Diosdado M (2008) Antiproliferative effect of proinflammatory citokines in cultured β cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like-peptide-1. J Mol Endocrinol 41:35-44.
10. Bosi E (2010) Time for testing incretin therapies in early type 1 diabetes? J Clin Endocrinol Metab 95:2607-2609.
11. Brussee V, Cunningham FA, and Zochodne DW (2004) Direct insulin signaling of neurons reverses diabetic neuropathy. Diabetes 53:1824-1830. (Pubitemid 38857041)
12. Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, Hughes TE, and Wang PR (2005) Acute and chronic effects of the incretin enhancer vildagliptin in insulinresistant rats. J Pharmacol Exp Ther 315:688-695. (Pubitemid 41500734)
13. Calcutt NA, Freshwater JD, and O'Brien JS (2000) Protection of sensory function and antihyperalgesic properties of a prosaposin-derived peptide in diabetic rats. Anesthesiology 93:1271-1278.
14. Coppey LJ, Davidson EP, Dunlap JA, Lund DD, and Yorek MA (2000) Slowing of motor nerve conduction velocity in streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles that overlie the sciatic nerve. Int J Exp Diabetes Res 1:131-143.
15. Courteix C, Eschalier A, and Lavarenne J (1993) Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 53:81-88. (Pubitemid 23137271)
16. Doss DJ, Kuruvilla R, Bianchi R, Peterson RG, and Eichberg J (1997) Effects of hypoxia and severity of diabetes on Na,K-ATPase activity and arachidonoylcontaining glycerophospholipid molecular species in nerve from streptozotocin diabetic rats. J Peripher Nerv Syst 2:155-163.
17. Dupre J (2005) Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Regul Pept 128:149-157.
18. Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, and Dejager S (2009) Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 11:157-166.
19. Harkavyi A and Whitton PS (2010) Glucagon-like peptide-1 receptor stimulation as a means of neuroprotection. Br J Pharmacol 159:495-501.
20. Himeno T, Kamiya H, Naruse K, Harada N, Ozaki N, Seino Y, Shibata T, Kondo M, Kato J, Okawa T, et al. (2011) Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes 60:2397-2406.
21. Huang TJ, Price SA, Chilton L, Calcutt NA, Tomlinson DR, Verkhratsky A, and Fernyhough P (2003) Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia. Diabetes 52:2129-2136. (Pubitemid 36919808)
22. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
23. Jin HY, Liu WJ, Park JH, Baek HS, and Park TS (2009) Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin- induced diabetic rats. Arch Med Res 40:536-544.
24. Jolivalt CG, Fineman M, Deacon CF, Carr RD, and Calcutt NA (2011) GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice. Diabetes Obes Metab 13:990-1000.
25. Lauria G, Morbin M, Lombardi R, Borgna M, Mazzoleni G, Sghirlanzoni A, and Pareyson D (2003) Axonal swellings predict the degeneration of epidermal nerve fibers in painful neuropathies. Neurology 61:631-636. (Pubitemid 37082599)
26. Liu WJ, Jin HY, Lee KA, Xie SH, Baek HS, and Park TS (2011) Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats. Br J Pharmacol 164:1410-1420.
27. Lovshin JA and Drucker DJ (2009) Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5:262-269.
28. Malcangio M and Tomlinson DR (1998) A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats. Pain 76:151-157. (Pubitemid 28304951)
29. McIntosh CH, Demuth HU, Kim SJ, Pospisilik JA, and Pederson RA (2006) Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. Int J Biochem Cell Biol 38:860-872. (Pubitemid 43363417)
30. Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA, and Greig NH (2007) Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 203:293-301. (Pubitemid 46157226)
31. Pierson CR, Zhang W, Murakawa Y, and Sima AA (2003) Insulin deficiency rather than hyperglycemia accounts for impaired neurotrophic responses and nerve fiber regeneration in type 1 diabetic neuropathy. J Neuropathol Exp Neurol 62:260-271. (Pubitemid 36330677)
32. Pospisilik JA, Ehses JA, Doty T, McIntosh CH, Demuth HU, and Pederson RA (2003) Dipeptidyl peptidase IV inhibition in animal models of diabetes. Adv Exp Med Biol 524:281-291.
33. Roglio I, Bianchi R, Gotti S, Scurati S, Giatti S, Pesaresi M, Caruso D, Panzica GC, and Melcangi RC (2008) Neuroprotective effects of dihydroprogesterone and progesterone in an experimental model of nerve crush injury. Neuroscience 155:673-685.
34. Romanovsky D, Cruz NF, Dienel GA, and Dobretsov M (2006) Mechanical hyperalgesia correlates with insulin deficiency in normoglycemic streptozotocin-treated rats. Neurobiol Dis 24:384-394. (Pubitemid 44572756)
35. Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, and Baron MA (2008) Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 31:30-35.
36. +-ATPase activity in the pathogenesis of human diabetic neuropathy. J Neurol Sci 120:159-167.
37. Sugimoto K, Rashid IB, Shoji M, Suda T, and Yasujima M (2008) Early changes in insulin receptor signaling and pain sensation in streptozotocin- induced diabetic neuropathy in rats. J Pain 9:237-245. (Pubitemid 351274070)
38. Tesfaye S (2009) Advances in the management of diabetic peripheral neuropathy. Curr Opin Support Palliat Care 3:136-143.
39. Toth C, Brussee V, and Zochodne DW (2006) Remote neurotrophic support of epidermal nerve fibres in experimental diabetes. Diabetologia 49:1081-1088.
40. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, and Hughes TE (2003) 1-[[(3-Hydroxy-1-adamantyl) amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 46:2774-2789. (Pubitemid 36702545)
41. Vinik AI, Park TS, Stansberry KB, and Pittenger GL (2000) Diabetic neuropathies. Diabetologia 43:957-973. (Pubitemid 30655714)